Osteoporosis International

, Volume 23, Issue 3, pp 1171–1176 | Cite as

Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide

  • S. A. Polyzos
  • A. D. Anastasilakis
  • C. Bratengeier
  • W. Woloszczuk
  • A. Papatheodorou
  • E. Terpos
Short Communication



Sclerostin is expressed by osteocytes and inhibits bone formation by osteoblasts. In this study, serum sclerostin was positively correlated with either lumbar spinal bone mineral density or T-score. Furthermore, serum sclerostin was increased after 6 months treatment with risedronate, whereas remained unchanged after 6 months teriparatide treatment.


The primary aim of this study was the evaluation of serum sclerostin levels in postmenopausal women and their association with bone mineral density (BMD) and bone turnover markers. The secondary aim was the evaluation of treatment with either teriparatide (TPTD) or risedronate (RIS) on serum sclerostin levels in women with postmenopausal osteoporosis.


Women with postmenopausal osteoporosis, assigned to receive either TPTD (TPTD group, n = 13) or RIS (RIS group, n = 36) for 6 months, and non-osteoporotic early postmenopausal women (NOEP group, n = 13) were recruited. Main outcome measure was serum sclerostin levels.


Serum sclerostin was higher in the NOEP group at baseline compared with either TPTD group (p = 0.007) or RIS group (p = 0.049). Sclerostin was positively correlated with both lumbar spinal (LS) BMD (r = 0.353; p = 0.005) and T-score (r = 0.501; p < 0.001) and negatively correlated with intact parathyroid hormone (r = −0.343; p = 0.024) at baseline. Multiple regression analysis showed that either LS BMD (Beta = 0.653; p = 0.018) or T-score (Beta = 0.711; p = 0.005) were independent predictors of serum sclerostin levels. No significant correlation was observed between serum sclerostin and bone turnover markers or estradiol at baseline. Sclerostin was significantly increased 6 months post-treatment in RIS group (p = 0.002), whereas remained statistically unaffected in the TPTD group.


Serum sclerostin is decreased in women with postmenopausal osteoporosis compared with non-osteoporotic early postmenopausal women and is positively correlated to either LS BMD or LS T-score. Furthermore, serum sclerostin was increased after 6 months treatment with RIS, whereas remained essentially unchanged after 6 months TPTD treatment.


Bisphosphonate Bone mineral density Dickoppf-1 Risedronate Sclerostin Teriparatide 


Conflicts of interest



  1. 1.
    Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99–107PubMedCrossRefGoogle Scholar
  2. 2.
    Trivedi R, Mithal A, Chattopadhyay N (2010) Anabolics in osteoporosis: the emerging therapeutic tool. Curr Mol Med 10:14–28PubMedCrossRefGoogle Scholar
  3. 3.
    Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van HW (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537–543PubMedCrossRefGoogle Scholar
  4. 4.
    Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842–1844PubMedGoogle Scholar
  5. 5.
    Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883–19887PubMedCrossRefGoogle Scholar
  6. 6.
    Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A, Niehrs C (2002) Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417:664–667PubMedCrossRefGoogle Scholar
  7. 7.
    Lewiecki EM (2009) Emerging drugs for postmenopausal osteoporosis. Expert Opin Emerg Drugs 14:129–144PubMedCrossRefGoogle Scholar
  8. 8.
    Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS (2010) Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 47:529–533PubMedCrossRefGoogle Scholar
  9. 9.
    Padhi D, Jang G, Stouch B, Fang L, Posvar E (2010) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. doi:10.1002/jbmr.173 Google Scholar
  10. 10.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, Efstathiadou Z, Kita M, Avramidis A (2008) Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. Int J Clin Pract 62:919–924PubMedCrossRefGoogle Scholar
  11. 11.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A (2008) Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Horm Metab Res 40:281–285PubMedCrossRefGoogle Scholar
  12. 12.
    Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E (2010) The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin Endocrinol Oxf 72:752–757PubMedCrossRefGoogle Scholar
  13. 13.
    Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Lawrence RB, Joseph ML III, Khosla S (2010) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. doi:10.1002/jbmr.217 Google Scholar
  14. 14.
    Melton LJ III, Looker AC, Shepherd JA, O’Connor MK, Achenbach SJ, Riggs BL, Khosla S (2005) Osteoporosis assessment by whole body region vs. site-specific DXA. Osteoporos Int 16:1558–1564PubMedCrossRefGoogle Scholar
  15. 15.
    Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056–5062PubMedCrossRefGoogle Scholar
  16. 16.
    Mirza FS, Padhi ID, Raisz LG, Lorenzo JA (2010) Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991–1997PubMedCrossRefGoogle Scholar
  17. 17.
    Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE (2010) Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248–2253PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2010

Authors and Affiliations

  • S. A. Polyzos
    • 1
  • A. D. Anastasilakis
    • 2
  • C. Bratengeier
    • 3
  • W. Woloszczuk
    • 4
  • A. Papatheodorou
    • 5
  • E. Terpos
    • 6
  1. 1.Second Medical Clinic, Medical SchoolAristotle University of Thessaloniki, Ippokration HospitalThessalonikiGreece
  2. 2.Department of Endocrinology424 General Military HospitalThessalonikiGreece
  3. 3.Biomarker Design Forschungs GmbHViennaAustria
  4. 4.Biomedica Medizinprodukte GmbH & Co KGViennaAustria
  5. 5.Department of Medical Research251 General Airforce HospitalAthensGreece
  6. 6.Department of Clinical Therapeutics, School of MedicineUniversity of AthensAthensGreece

Personalised recommendations